Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 418

1.

Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.

Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ.

J Pharmacol Exp Ther. 2009 Nov;331(2):574-90. doi: 10.1124/jpet.109.155994. Epub 2009 Aug 6.

2.

Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ.

Neuropharmacology. 2006 Aug;51(2):386-96. Epub 2006 Jun 15.

PMID:
16780899
3.

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.

Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS.

J Pharmacol Exp Ther. 2008 May;325(2):681-90. doi: 10.1124/jpet.107.132910. Epub 2008 Feb 20.

4.

Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.

Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ.

Curr Opin Investig Drugs. 2007 Jan;8(1):54-9. Review.

PMID:
17263185
5.

WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.

Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR Jr, Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S.

J Pharmacol Exp Ther. 2007 Jan;320(1):486-96. Epub 2006 Oct 12.

6.

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.

Smith SM, Uslaner JM, Cox CD, Huszar SL, Cannon CE, Vardigan JD, Eddins D, Toolan DM, Kandebo M, Yao L, Raheem IT, Schreier JD, Breslin MJ, Coleman PJ, Renger JJ.

Neuropharmacology. 2013 Jan;64:215-23. doi: 10.1016/j.neuropharm.2012.06.013. Epub 2012 Jun 27.

PMID:
22750078
7.

Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.

Verhoest PR, Chapin DS, Corman M, Fonseca K, Harms JF, Hou X, Marr ES, Menniti FS, Nelson F, O'Connor R, Pandit J, Proulx-Lafrance C, Schmidt AW, Schmidt CJ, Suiciak JA, Liras S.

J Med Chem. 2009 Aug 27;52(16):5188-96. doi: 10.1021/jm900521k.

PMID:
19630403
8.

Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs.

Megens AA, Hendrickx HM, Hens KA, Fonteyn I, Langlois X, Lenaerts I, Somers MV, de Boer P, Vanhoof G.

J Pharmacol Exp Ther. 2014 Apr;349(1):138-54. doi: 10.1124/jpet.113.211904. Epub 2014 Jan 13.

9.

Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.

Kleiman RJ, Kimmel LH, Bove SE, Lanz TA, Harms JF, Romegialli A, Miller KS, Willis A, des Etages S, Kuhn M, Schmidt CJ.

J Pharmacol Exp Ther. 2011 Jan;336(1):64-76. doi: 10.1124/jpet.110.173294. Epub 2010 Oct 5.

10.

Patterns of brain glucose metabolism induced by phosphodiesterase 10A inhibitors in the mouse: a potential translational biomarker.

Dedeurwaerdere S, Wintmolders C, Vanhoof G, Langlois X.

J Pharmacol Exp Ther. 2011 Oct;339(1):210-7. doi: 10.1124/jpet.111.182766. Epub 2011 Jul 8.

11.

Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.

Hebb AL, Robertson HA, Denovan-Wright EM.

Eur Neuropsychopharmacol. 2008 May;18(5):339-63. Epub 2007 Oct 29.

PMID:
17913473
12.

Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background.

Siuciak JA, McCarthy SA, Chapin DS, Martin AN, Harms JF, Schmidt CJ.

Neuropharmacology. 2008 Feb;54(2):417-27. Epub 2007 Dec 3.

PMID:
18061215
13.

Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum.

Wilson JM, Ogden AM, Loomis S, Gilmour G, Baucum AJ 2nd, Belecky-Adams TL, Merchant KM.

Neuropharmacology. 2015 Dec;99:379-86. doi: 10.1016/j.neuropharm.2015.08.008. Epub 2015 Aug 7.

PMID:
26256420
14.

Deficient prepulse inhibition of acoustic startle in Hooded-Wistar rats compared with Sprague-Dawley rats.

van den Buuse M.

Clin Exp Pharmacol Physiol. 2003 Apr;30(4):254-61.

PMID:
12680843
15.

Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating.

Gresack JE, Seymour PA, Schmidt CJ, Risbrough VB.

Psychopharmacology (Berl). 2014 May;231(10):2189-97. doi: 10.1007/s00213-013-3371-7. Epub 2013 Dec 21.

16.

The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents.

Gentzel RC, Toolan D, Roberts R, Koser AJ, Kandebo M, Hershey J, Renger JJ, Uslaner J, Smith SM.

Neuropharmacology. 2015 Dec;99:256-63. doi: 10.1016/j.neuropharm.2015.05.024. Epub 2015 Jun 2.

PMID:
26044638
17.

Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A.

Strick CA, James LC, Fox CB, Seeger TF, Menniti FS, Schmidt CJ.

Neuropharmacology. 2010 Feb;58(2):444-51. doi: 10.1016/j.neuropharm.2009.09.008. Epub 2009 Sep 16.

PMID:
19765598
18.

In vivo pharmacological characterization of TAK-063, a potent and selective phosphodiesterase 10A inhibitor with antipsychotic-like activity in rodents.

Suzuki K, Harada A, Shiraishi E, Kimura H.

J Pharmacol Exp Ther. 2015 Mar;352(3):471-9. doi: 10.1124/jpet.114.218552. Epub 2014 Dec 18.

19.

ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.

Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, Pulicicchio C, Day M, Gilbert A, Pausch MH, Brandon NJ, Beyer CE, Comery TA, Logue S, Rosenzweig-Lipson S, Marquis KL.

J Pharmacol Exp Ther. 2008 Dec;327(3):827-39. doi: 10.1124/jpet.108.136580. Epub 2008 Aug 27.

20.

Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A.

Redrobe JP, Rasmussen LK, Christoffersen CT, Bundgaard C, Jørgensen M.

Eur J Pharmacol. 2015 Aug 15;761:79-85. doi: 10.1016/j.ejphar.2015.04.040. Epub 2015 May 2.

PMID:
25941078

Supplemental Content

Support Center